How And Where Tougher Clinical Evaluation Measures Under EU MDR Cause Challenges
A first of its kind study examines how large compared with medium companies are coping with the EU’s strict clinical evidence requirements. The results show how it is the more stringent demands for high-risk devices that are leading to device removals as well as market launch outside the EU.
You may also be interested in...
Is The Implementation Of The EU Medtech Regulatory Structure Entering A New Phase?
Three weeks have gone by now since the European Commission published a “latest update” on the medical device sector pages of its website. What does this mean for the sector?
Annex XVI Products Set To Have More Time To Comply With MDR
Devices without a clinical purpose that fall under the scope of the EU’s Medical Device Regulation need to be tightly regulated. Now it looks as though manufacturers will have more time to comply if they need it.
EU Guidance On 'Significant Change' Meaning For Legacy Products Is Updated
Now that the deadlines for legacy products under the EU’s Medical Device Regulation have been extended, the vital guidance on the meaning of “significant change” and conditions for ongoing sale of these products has also been updated.